is bpc 157 local or systemic BPC-157 and the Difference Between an Evidence Gap and a Cover-Up: What the entire human evidence base actually looks like, and the questions to ask next. — WellFounded BPC-157 therapy in the cardiovascular

BPC-157 modulates nitric oxide synthase (NOS) activity, specifically reducing inducible NOS (iNOS) expression triggered by inflammatory injury while preserving endothelial NOS (eNOS) activity needed for vascular integrity

KPV and MOTS-C had no human studies at all

Other reported side effects are: Headache Dizziness Fatigue Nausea Elevated blood pressure Lowered blood pressure Increase in appetite Redness and pain at the injection site Cramping at the injection site How Do I Know What Dosage I Need to Take

Bone 51 , 241248 (2012)

Use a 90-degree angle when there is adequate tissue depth and no pinch is needed

Diagen is the company that currently owns the BPC-157 US patent (the European patent is expired), which was filed in 2012, approved in 2017 with an expected expiration of 2033